>>> MRK - FDA grants orphan drug designation for Pembrolizumab for treatment of FDA grants orphan drug designation for Pembrolizumab for treatment of Small Cell Lung Cancer excluding those that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatched repair deficient (dMMR)